VitriVax provides a formulation technology platform (ALTA®) that creates thermostable, single‑dose vaccines stable up to 70 °C for months, removing the need for refrigeration and multiple administrations. By combining spray‑drying encapsulation with atomic layer deposition of nanometer‑thin metal‑oxide coatings, the platform enables controlled, sustained release of antigen and adjuvant, supporting scalable manufacturing for vaccine developers, pharma manufacturers, and public‑health agencies targeting remote or resource‑limited settings.
Funding
$17.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Vaccines often require a continuous cold chain and multiple administrations to achieve protective immunity, which limits distribution to remote or resource‑constrained regions and reduces patient adherence.
Solution
VitriVax’s Atomic Layering Thermostable Antigen and Adjuvant (ALTA®) platform creates vaccines that remain stable at temperatures up to 70 °C for extended periods, eliminating the need for refrigeration during transport and storage. The technology combines spray‑drying encapsulation in a sugar‑glass matrix with atomic layer deposition of nanometer‑thin metal‑oxide coatings, enabling controlled, timed release of antigen and adjuvant for up to six months after a single injection. By using commercially available, GRAS‑approved equipment and ingredients, ALTA® supports scalable manufacturing of single‑dose, thermostable vaccines suitable for global deployment, including emergency and military applications.
Target Audience
Primary customers are vaccine developers, pharmaceutical manufacturers, and public‑health agencies seeking thermostable, single‑dose vaccine solutions for human and animal immunization programs.
Features
- Spray‑drying encapsulation of antigens in a protective sugar‑glass matrix that preserves thermal and chemical stability up to 70 °C
- Atomic layer deposition (ALD) of nanometer‑thin metal‑oxide shells on microparticles to achieve programmable, sustained antigen/adjuvant release for up to six months
- Single‑dose formulation eliminates the need for multi‑visit vaccination schedules, improving adherence
- Manufacturing process relies on widely available, FDA‑approved equipment and GRAS ingredients, facilitating rapid scale‑up
- Reduced cold‑chain requirements enable distribution to remote, low‑resource, or disaster‑affected areas